Here is the breakdown of the findings released today: Unprecedented Weight Loss: At 68 weeks, patients on the 12mg dose achieved an average weight loss of 28.7%
This type of injury happens fast
In people with established CVD, a GLP-1 RA with proven benefit should be used to reduce MACE, or an SGLT2i with proven benefit should be used to reduce MACE and HF and improve kidney outcomes
Participants were randomized 1:1:1 to retatrutide 9 mg weekly, retatrutide 12 mg weekly, or placebo, and treated for 68 weeks
Ostman B, Sjodin A, Michaelsson K, Byberg L
SGLT2 vs Dual Agonists: Putting Weight Loss in Context SGLT2 inhibitors like empagliflozin (Jardiance) offer modest weight reduction of approximately 4 to 6 pounds, a fraction of what dual agonists deliver